Frontiers in Cardiovascular Drug Discovery

Volume 3


Atta-ur-Rahman, FRS , M. Iqbal Choudhary

DOI: 10.2174/97816810816321160301
eISBN: 978-1-68108-163-2, 2016
ISBN: 978-1-68108-164-9
ISSN: 2452-3267 (Print)
ISSN: 1879-6648 (Online)

Indexed in: Book Citation Index, EMBASE, Chemical Abstracts, EBSCO

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publis...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology

Evolution of Heart Failure Pharmacotherapy

- Pp. 62-147 (86)

Gurpreet Sodhi, Ju Kim, Stephen Robie and Gurusher Panjrath


Heart Failure is a chronic disease with increasing prevalence around the world. It is associated with significant mortality, morbidity, and healthcare costs. Over the past 2-3 decades, major advances in drug development have contributed significantly in decreasing mortality among those with chronic systolic heart failure. However, similar advances are missing in patients experiencing acute heart failure and heart failure with preserved ejection fraction. In the current chapter, we will review the historical development of pharmacotherapy in heart failure medical management. A comparative review of contribution of each class towards reducing mortality will be performed. More importantly, drugs which failed to succeed or impact significantly will be reviewed and an insight on why they may have failed will be provided. Development of new drugs is limited by regulatory requirements as well as disease heterogeneity. New agents under development will be summarized and mode of their action will be detailed. This chapter aims to serve as a comprehensive resource on strategies both past and current as well as provide discussion regarding potential future developments in heart failure pharmacotherapy.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2019 Bentham Science